1	Allogeneic	Allogeneic	B-NP	JJ	O	2	NMOD	0
2	injection	injection	I-NP	NN	O	9	SUB	19	injection
3	of	of	B-PP	IN	O	2	NMOD	0
4	fetal	fetal	B-NP	JJ	B-cell_type	8	NMOD	0
5	membrane-derived	membrane-derived	I-NP	JJ	I-cell_type	8	NMOD	0
6	mesenchymal	mesenchymal	I-NP	JJ	I-cell_type	8	NMOD	0
7	stem	stem	I-NP	NN	I-cell_type	8	NMOD	0
8	cells	cell	I-NP	NNS	I-cell_type	3	PMOD	0
9	induces	induce	B-VP	VBZ	O	0	ROOT	17	induces
10	therapeutic	therapeutic	B-NP	JJ	O	11	NMOD	0
11	angiogenesis	angiogenesis	I-NP	NN	O	9	OBJ	3	angiogenesis
12	in	in	B-PP	IN	O	9	VMOD	0
13	a	a	B-NP	DT	O	15	NMOD	0
14	rat	rat	I-NP	NN	O	15	NMOD	0
15	model	model	I-NP	NN	O	12	PMOD	0
16	of	of	B-PP	IN	O	15	NMOD	0
17	hind	hind	B-NP	NN	O	19	NMOD	0
18	limb	limb	I-NP	NN	O	19	NMOD	0
19	ischemia	ischemia	I-NP	NN	O	16	PMOD	0
20	.	.	O	.	O	9	P	0

1	Bone	Bone	B-NP	NN	B-cell_line	5	NMOD	0
2	marrow-derived	marrow-derived	I-NP	JJ	I-cell_line	5	NMOD	0
3	mesenchymal	mesenchymal	I-NP	JJ	I-cell_line	5	NMOD	0
4	stem	stem	I-NP	NN	I-cell_line	5	NMOD	0
5	cells	cell	I-NP	NNS	I-cell_line	9	SUB	0
6	(	(	O	(	O	8	DEP	0
7	BM-MSC	BM-MSC	B-NP	NN	B-cell_line	8	DEP	0
8	)	)	O	)	O	5	NMOD	0
9	have	have	B-VP	VBP	O	0	ROOT	0
10	been	be	I-VP	VBN	O	9	VC	0
11	demonstrated	demonstrate	I-VP	VBN	O	10	VC	0
12	to	to	I-VP	TO	O	13	VMOD	0
13	be	be	I-VP	VB	O	11	VMOD	0
14	an	an	B-NP	DT	O	18	NMOD	0
15	attractive	attractive	I-NP	JJ	O	18	NMOD	0
16	therapeutic	therapeutic	I-NP	JJ	O	18	NMOD	0
17	cell	cell	I-NP	NN	O	18	NMOD	0
18	source	source	I-NP	NN	O	13	PRD	0
19	for	for	B-PP	IN	O	18	NMOD	0
20	tissue	tissue	B-NP	NN	O	21	NMOD	0
21	regeneration	regeneration	I-NP	NN	O	23	NMOD	2	regeneration
22	and	and	I-NP	CC	O	23	NMOD	0
23	repair	repair	I-NP	NN	O	19	PMOD	2	repair
24	.	.	O	.	O	9	P	0

1	However	However	B-ADVP	RB	O	4	VMOD	0
2	,	,	O	,	O	4	P	0
3	it	it	B-NP	PRP	O	4	SUB	0
4	remains	remain	B-VP	VBZ	O	0	ROOT	0
5	unknown	unknown	B-ADJP	JJ	O	4	PRD	0
6	whether	whether	B-SBAR	IN	O	4	VMOD	0
7	or	or	O	CC	O	6	DEP	0
8	not	not	O	RB	O	9	AMOD	0
9	allogeneic	allogeneic	B-NP	JJ	O	10	NMOD	0
10	transplantation	transplantation	I-NP	NN	O	36	SUB	19	transplantation
11	of	of	B-PP	IN	O	10	NMOD	0
12	mesenchymal	mesenchymal	B-NP	JJ	B-cell_type	14	NMOD	0
13	stem	stem	I-NP	NN	I-cell_type	14	NMOD	0
14	cells	cell	I-NP	NNS	I-cell_type	11	PMOD	0
15	(	(	O	(	O	17	DEP	0
16	MSC	MSC	B-NP	NN	B-cell_type	17	DEP	0
17	)	)	O	)	O	14	NMOD	0
18	derived	derive	B-VP	VBN	O	14	NMOD	0
19	from	from	B-PP	IN	O	18	VMOD	0
20	fetal	fetal	B-NP	JJ	O	21	NMOD	0
21	membranes	membrane	I-NP	NNS	O	19	PMOD	0
22	(	(	O	(	O	24	DEP	0
23	FM	FM	B-NP	NNS	O	24	DEP	0
24	)	)	O	)	O	21	NMOD	0
25	,	,	O	,	O	21	P	0
26	which	which	B-NP	WDT	O	21	NMOD	0
27	are	be	B-VP	VBP	O	26	SBAR	0
28	generally	generally	I-VP	RB	O	27	VMOD	0
29	discarded	discard	I-VP	VBN	O	27	VC	0
30	as	as	B-PP	IN	O	29	VMOD	0
31	medical	medical	B-NP	JJ	O	32	NMOD	0
32	waste	waste	I-NP	NN	O	30	PMOD	0
33	after	after	B-PP	IN	O	32	NMOD	0
34	delivery	delivery	B-NP	NN	O	33	PMOD	0
35	,	,	O	,	O	10	P	0
36	has	have	B-VP	VBZ	O	6	SBAR	0
37	therapeutic	therapeutic	B-NP	JJ	O	38	NMOD	0
38	potential	potential	I-NP	NN	O	36	OBJ	0
39	.	.	O	.	O	4	P	0

1	FM-MSC	FM-MSC	B-NP	NN	B-protein	2	SUB	0
2	were	be	B-VP	VBD	O	0	ROOT	0
3	obtained	obtain	I-VP	VBN	O	2	VC	19	obtained
4	from	from	B-PP	IN	O	3	VMOD	0
5	Lewis	Lewis	B-NP	NNP	O	6	NMOD	0
6	rats	rat	I-NP	NNS	O	4	PMOD	0
7	and	and	O	CC	O	2	VMOD	0
8	had	have	B-VP	VBD	O	2	VMOD	0
9	surface	surface	B-NP	NN	O	11	NMOD	0
10	antigen	antigen	I-NP	NN	O	11	NMOD	0
11	expression	expression	I-NP	NN	O	8	OBJ	0
12	and	and	O	CC	O	11	NMOD	0
13	multipotent	multipotent	B-NP	JJ	O	14	NMOD	0
14	potential	potential	I-NP	NN	O	12	PMOD	0
15	partly	partly	B-ADJP	RB	O	16	AMOD	0
16	similar	similar	I-ADJP	JJ	O	14	NMOD	0
17	to	to	B-PP	TO	O	16	AMOD	0
18	those	those	B-NP	DT	O	17	PMOD	0
19	of	of	B-PP	IN	O	18	NMOD	0
20	BM-MSC	BM-MSC	B-NP	NN	B-protein	19	PMOD	0
21	.	.	O	.	O	2	P	0

1	Compared	Compare	B-PP	VBN	O	6	VMOD	0
2	with	with	B-PP	IN	O	1	PMOD	0
3	BM-MSC	BM-MSC	B-NP	NNP	O	2	PMOD	0
4	,	,	O	,	O	6	P	0
5	FM-MSC	FM-MSC	B-NP	NNP	O	6	SUB	0
6	secreted	secrete	B-VP	VBD	O	0	ROOT	14	secreted
7	a	a	B-NP	DT	O	9	NMOD	0
8	comparable	comparable	I-NP	JJ	O	9	NMOD	0
9	amount	amount	I-NP	NN	O	6	OBJ	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	hepatocyte	hepatocyte	B-NP	NN	B-protein	13	NMOD	0
12	growth	growth	I-NP	NN	I-protein	13	NMOD	0
13	factor	factor	I-NP	NN	I-protein	10	PMOD	0
14	despite	despite	B-PP	IN	O	6	VMOD	0
15	a	a	B-NP	DT	O	17	NMOD	0
16	small	small	I-NP	JJ	O	17	NMOD	0
17	amount	amount	I-NP	NN	O	14	PMOD	0
18	of	of	B-PP	IN	O	17	NMOD	0
19	vascular	vascular	B-NP	JJ	B-protein	22	NMOD	0
20	endothelial	endothelial	I-NP	JJ	I-protein	22	NMOD	0
21	growth	growth	I-NP	NN	I-protein	22	NMOD	0
22	factor	factor	I-NP	NN	I-protein	18	PMOD	0
23	.	.	O	.	O	6	P	0

1	FM-MSC	FM-MSC	B-NP	NNP	O	3	NMOD	0
2	and	and	I-NP	CC	O	3	NMOD	0
3	BM-MSC	BM-MSC	I-NP	NNP	O	0	ROOT	0
4	both	both	O	CC	O	3	NMOD	0
5	expressed	express	B-VP	VBD	O	4	DEP	0
6	major	major	B-NP	JJ	O	8	NMOD	0
7	histocompatibility	histocompatibility	I-NP	NN	O	8	NMOD	0
8	complex	complex	I-NP	NN	O	19	NMOD	0
9	(	(	O	(	O	11	DEP	0
10	MHC	MHC	B-NP	NN	O	11	DEP	0
11	)	)	O	)	O	8	NMOD	0
12	class	class	B-NP	NN	O	19	NMOD	0
13	I	I	I-NP	CD	O	19	NMOD	0
14	but	but	B-NP	CC	O	19	NMOD	0
15	not	not	I-NP	RB	O	14	DEP	0
16	MHC	MHC	B-NP	NN	B-protein	19	NMOD	0
17	class	class	I-NP	NN	I-protein	19	NMOD	0
18	II	II	B-NP	CD	I-protein	19	NMOD	0
19	antigens	antigen	I-NP	NNS	I-protein	5	OBJ	0
20	and	and	O	CC	O	5	VMOD	0
21	did	do	B-VP	VBD	O	5	VMOD	0
22	not	not	I-VP	RB	O	21	VMOD	0
23	elicit	elicit	I-VP	VB	O	21	VC	0
24	allogeneic	allogeneic	B-NP	JJ	O	26	NMOD	0
25	lymphocyte	lymphocyte	I-NP	NN	O	26	NMOD	0
26	proliferation	proliferation	I-NP	NN	O	23	OBJ	1	proliferation
27	in	in	B-PP	IN	O	26	NMOD	0
28	mixed	mixed	B-NP	JJ	B-cell_line	30	NMOD	0
29	lymphocyte	lymphocyte	I-NP	NN	I-cell_line	30	NMOD	0
30	culture	culture	I-NP	NN	I-cell_line	27	PMOD	0
31	.	.	O	.	O	3	P	0

1	FM-MSC	FM-MSC	B-NP	NN	O	3	NMOD	0
2	or	or	I-NP	CC	O	3	NMOD	0
3	BM-MSC	BM-MSC	I-NP	NN	O	8	SUB	0
4	obtained	obtain	B-VP	VBN	O	3	NMOD	19	obtained
5	from	from	B-PP	IN	O	4	VMOD	0
6	Lewis	Lewis	B-NP	NNP	O	7	NMOD	0
7	rats	rat	I-NP	NNS	O	5	PMOD	0
8	were	be	B-VP	VBD	O	0	ROOT	0
9	injected	inject	I-VP	VBN	O	8	VC	19	injected
10	into	into	B-PP	IN	O	9	VMOD	0
11	a	a	B-NP	DT	O	15	NMOD	0
12	MHC-mismatched	MHC-mismatched	I-NP	JJ	O	15	NMOD	0
13	August-Copenhagen-Irish	August-Copenhagen-Irish	I-NP	JJ	O	15	NMOD	0
14	rat	rat	I-NP	NN	O	15	NMOD	0
15	model	model	I-NP	NN	O	10	PMOD	0
16	of	of	B-PP	IN	O	15	NMOD	0
17	hind	hind	B-NP	NN	O	19	NMOD	0
18	limb	limb	I-NP	NN	O	19	NMOD	0
19	ischemia	ischemia	I-NP	NN	O	16	PMOD	0
20	.	.	O	.	O	8	P	0

1	Three	Three	B-NP	CD	O	2	NMOD	0
2	weeks	week	I-NP	NNS	O	3	PMOD	0
3	after	after	B-PP	IN	O	11	VMOD	0
4	injection	injection	B-NP	NN	O	3	PMOD	0
5	,	,	O	,	O	11	P	0
6	blood	blood	B-NP	NN	O	7	NMOD	0
7	perfusion	perfusion	I-NP	NN	O	10	NMOD	0
8	and	and	O	CC	O	10	NMOD	0
9	capillary	capillary	B-NP	JJ	O	10	NMOD	0
10	density	density	I-NP	NN	O	11	SUB	0
11	were	be	B-VP	VBD	O	32	VMOD	0
12	significantly	significantly	B-ADJP	RB	O	13	AMOD	0
13	higher	high	I-ADJP	JJR	O	11	PRD	0
14	in	in	B-PP	IN	O	11	VMOD	0
15	the	the	B-NP	DT	O	19	NMOD	0
16	FM-MSC	FM-MSC	I-NP	NNP	O	19	NMOD	0
17	and	and	I-NP	CC	O	19	NMOD	0
18	BM-MSC	BM-MSC	I-NP	NNP	O	19	NMOD	0
19	groups	group	I-NP	NNS	O	14	PMOD	0
20	than	than	B-PP	IN	O	11	VMOD	0
21	in	in	B-PP	IN	O	20	PMOD	0
22	the	the	B-NP	DT	O	25	NMOD	0
23	phosphate-buffered	phosphate-buffered	I-NP	JJ	O	25	NMOD	0
24	saline	saline	I-NP	NN	O	25	NMOD	0
25	group	group	I-NP	NN	O	21	PMOD	0
26	,	,	O	,	O	32	P	0
27	and	and	O	CC	O	31	NMOD	0
28	allogeneic	allogeneic	B-NP	JJ	O	29	NMOD	0
29	FM-MSC	FM-MSC	I-NP	NN	O	31	NMOD	0
30	and	and	I-NP	CC	O	31	NMOD	0
31	BM-MSC	BM-MSC	I-NP	NN	B-protein	32	SUB	0
32	were	be	B-VP	VBD	O	0	ROOT	0
33	still	still	I-VP	RB	O	32	VMOD	0
34	observed	observe	I-VP	VBN	O	32	VC	19	observed
35	.	.	O	.	O	32	P	0

1	In	In	B-PP	IN	O	12	VMOD	0
2	nonischemic	nonischemic	B-NP	JJ	O	5	NMOD	0
3	hind	hind	I-NP	NN	O	5	NMOD	0
4	limb	limb	I-NP	NN	O	5	NMOD	0
5	tissues	tissue	I-NP	NNS	O	1	PMOD	0
6	,	,	O	,	O	12	P	0
7	allogeneic	allogeneic	B-NP	JJ	O	8	NMOD	0
8	FM-MSC	FM-MSC	I-NP	NN	O	11	NMOD	0
9	and	and	I-NP	CC	O	11	NMOD	0
10	BM-MSC	BM-MSC	I-NP	NN	O	11	NMOD	0
11	injection	injection	I-NP	NN	O	12	SUB	19	injection
12	were	be	B-VP	VBD	O	0	ROOT	0
13	associated	associate	I-VP	VBN	O	12	VC	0
14	with	with	B-PP	IN	O	13	VMOD	0
15	a	a	B-NP	DT	O	18	NMOD	0
16	comparatively	comparatively	I-NP	RB	O	17	AMOD	0
17	small	small	I-NP	JJ	O	18	NMOD	0
18	amount	amount	I-NP	NN	O	14	PMOD	0
19	of	of	B-PP	IN	O	18	NMOD	0
20	T	T	B-NP	NN	B-cell_type	22	NMOD	0
21	lymphocyte	lymphocyte	I-NP	NN	I-cell_type	22	NMOD	0
22	infiltration	infiltration	I-NP	NN	O	19	PMOD	14	infiltration
23	,	,	O	,	O	13	P	0
24	compared	compare	B-PP	VBN	O	13	VMOD	0
25	with	with	B-PP	IN	O	24	VMOD	0
26	the	the	B-NP	DT	O	27	NMOD	0
27	injection	injection	I-NP	NN	O	25	PMOD	19	injection
28	of	of	B-PP	IN	O	27	NMOD	0
29	allogeneic	allogeneic	B-NP	JJ	B-cell_type	31	NMOD	0
30	splenic	splenic	I-NP	JJ	I-cell_type	31	NMOD	0
31	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	28	PMOD	0
32	.	.	O	.	O	12	P	0

1	In	In	B-PP	IN	O	7	VMOD	0
2	conclusion	conclusion	B-NP	NN	O	1	PMOD	0
3	,	,	O	,	O	7	P	0
4	allogeneic	allogeneic	B-NP	JJ	O	6	NMOD	0
5	FM-MSC	FM-MSC	I-NP	JJ	O	6	NMOD	0
6	injection	injection	I-NP	NN	O	7	SUB	19	injection
7	did	do	B-VP	VBD	O	0	ROOT	0
8	not	not	I-VP	RB	O	7	VMOD	0
9	elicit	elicit	I-VP	VB	O	7	VC	17	elicit
10	a	a	B-NP	DT	O	13	NMOD	0
11	lymphocyte	lymphocyte	I-NP	NN	O	13	NMOD	0
12	proliferative	proliferative	I-NP	JJ	O	13	NMOD	0
13	response	response	I-NP	NN	O	9	OBJ	0
14	and	and	O	CC	O	7	VMOD	0
15	provided	provide	B-VP	VBD	O	7	VMOD	0
16	significant	significant	B-NP	JJ	O	17	NMOD	0
17	improvement	improvement	I-NP	NN	O	15	OBJ	0
18	in	in	B-PP	IN	O	17	NMOD	0
19	a	a	B-NP	DT	O	21	NMOD	0
20	rat	rat	I-NP	NN	O	21	NMOD	0
21	model	model	I-NP	NN	O	18	PMOD	0
22	of	of	B-PP	IN	O	21	NMOD	0
23	hind	hind	B-NP	NN	O	25	NMOD	0
24	limb	limb	I-NP	NN	O	25	NMOD	0
25	ischemia	ischemia	I-NP	NN	O	22	PMOD	0
26	,	,	O	,	O	17	P	0
27	comparable	comparable	B-ADJP	JJ	O	17	NMOD	0
28	to	to	B-PP	TO	O	27	AMOD	0
29	the	the	B-NP	DT	O	30	NMOD	0
30	response	response	I-NP	NN	O	28	PMOD	0
31	to	to	B-PP	TO	O	30	NMOD	0
32	BM-MSC	BM-MSC	B-NP	NNP	B-cell_type	31	PMOD	0
33	.	.	O	.	O	7	P	0

1	Thus	Thus	B-ADVP	RB	O	7	VMOD	0
2	,	,	O	,	O	7	P	0
3	allogeneic	allogeneic	B-NP	JJ	O	4	NMOD	0
4	injection	injection	I-NP	NN	O	7	SUB	19	injection
5	of	of	B-PP	IN	O	4	NMOD	0
6	FM-MSC	FM-MSC	B-NP	NNP	O	5	PMOD	0
7	may	may	B-VP	MD	O	0	ROOT	0
8	be	be	I-VP	VB	O	7	VC	0
9	a	a	B-NP	DT	O	12	NMOD	0
10	new	new	I-NP	JJ	O	11	AMOD	0
11	therapeutic	therapeutic	I-NP	JJ	O	12	NMOD	0
12	strategy	strategy	I-NP	NN	O	8	PRD	0
13	for	for	B-PP	IN	O	12	NMOD	0
14	the	the	B-NP	DT	O	15	NMOD	0
15	treatment	treatment	I-NP	NN	O	13	PMOD	0
16	of	of	B-PP	IN	O	15	NMOD	0
17	severe	severe	B-NP	JJ	O	20	NMOD	0
18	peripheral	peripheral	I-NP	JJ	O	20	NMOD	0
19	vascular	vascular	I-NP	JJ	O	20	NMOD	0
20	disease	disease	I-NP	NN	O	16	PMOD	0
21	.	.	O	.	O	7	P	0

1	Disclosure	Disclosure	B-NP	NN	O	7	SUB	0
2	of	of	B-PP	IN	O	1	NMOD	0
3	potential	potential	B-NP	JJ	O	4	NMOD	0
4	conflicts	conflict	I-NP	NNS	O	2	PMOD	0
5	of	of	B-PP	IN	O	4	NMOD	0
6	interest	interest	B-NP	NN	O	5	PMOD	0
7	is	be	B-VP	VBZ	O	0	ROOT	0
8	found	find	I-VP	VBN	O	7	VC	0
9	at	at	B-PP	IN	O	8	VMOD	0
10	the	the	B-NP	DT	O	11	NMOD	0
11	end	end	I-NP	NN	O	9	PMOD	0
12	of	of	B-PP	IN	O	11	NMOD	0
13	this	this	B-NP	DT	O	14	NMOD	0
14	article	article	I-NP	NN	O	12	PMOD	0
15	.	.	O	.	O	7	P	0

